3 results
To assess the efficacy of nab-paclitaxel administered intravenously (IV) on Days 8and 15 with epigenetic modifying therapy of CC-486 once daily (QD) on Days 1 to14 every 21 days, and nab-paclitaxel monotherapy administered IV on Days 1 and 8every 21…
The primary objective is to demonstrate non-inferiority of patients bilaterally implanted with the AcrySof® IQ ReSTOR® +2.5 D MIOL to AcrySof® IQ ReSTOR® +2.5 D MIOL in the dominant eye and AcrySof® IQ ReSTOR® +3.0 D in the fellow eye in binocular…
Primary objectivePhase 1: To assess the safety and tolerability of Nab-paclitaxel added to oxaliplatin and capecitabine at their currently optimal doses.Phase 2: To determine the anti-tumor activity of Nab-paclitaxel when co-administered with…